What We're Reading: Page 149
Industry reads hand-picked by our editors
Sep 29, 2021
-
The Boston Globe
Mass General Brigham won't offer Biogen’s new Alzheimer's drug
-
Bloomberg
I-Mab Said to Weigh Partnership, Stake Sale to Pharma Giants
-
The Wall Street Journal
India Aims to Produce mRNA Covid-19 Vaccine This Year
-
Reuters
U.S. FDA approves AbbVie's migraine prevention drug
Sep 28, 2021
-
The Wall Street Journal
Merck Nears Deal to Acquire Acceleron Pharma
-
The New York Times
Cancer Without Chemotherapy: 'A Totally Different World'
-
Endpoints News
The coronavirus vaccine that the world forgot could still help save it
-
C&EN
How the drug services industry found itself prepared for a pandemic
Sep 27, 2021
-
Bloomberg
Acceleron Is Said to Be in Advanced Talks for $11 Billion Sale
-
The Washington Post
Changes in covid booster shot guidance lead to confusion, chaos for doctors and the vaccinated
-
STAT
Democrats’ opposition to drug pricing reform is shrinking, ahead of key vote
-
Axios
Pfizer CEO: Company will submit data for children's vaccine to FDA in "days"
Sep 24, 2021
-
The Wall Street Journal
M&A Banker Found Promise in Nascent Biotechnology Companies
-
Kaiser Health News
Biosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch?
-
Reuters
Doctors scale rockslides, invoke gods to vaccinate Himalayan villages
Sep 23, 2021
-
POLITICO
Pfizer CEO rallies staff to fight Democrats' drug price negotiation
-
Bloomberg
Vaccinated Pregnant Women Pass Protection to Babies in Study
-
Financial Times
Activist Bluebell takes stake in GlaxoSmithKline to push for change at top
-
Evaluate Vantage
The heat is on Gilead as Tropics readout nears
Sep 22, 2021
-
STAT
Biogen considers cost-cutting measures after slow Aduhelm sales
-
The New York Times
Pressure Grows on U.S. Companies to Share Covid Vaccine Technology
-
Fierce Pharma
Amgen scores Otezla patent win, nabbing protection until 2028
-
NPR
The FDA Has Been Without A Permanent Leader For 8 Months, As COVID Cases Climb
Previous
